Estradiol agonists inhibit human lovo colorectal-cancer cell proliferation and migration through p53

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16665-16673

  Hsu, Hsi Hsien ^a   Kuo, Wei Wen ^b   Ju, Da Tong ^c   Yeh, Yu Lan ^d   Tu, Chuan Chou ^e   Tsai, Ying Lan ^f   Shen, Chia Yao ^g   Chang, Sheng Huang ^h   Chung, Li Chin ⁱ   Huang, Chih Yang ^c,j,k  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN SPORT UNIVERSITY   (Taiwan)

^h MEIHO UNIVERSITY   (Taiwan)

ⁱ Tsaotun Psychiatric Center   (Taiwan)

^j CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^k ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

Estrogen; Estrogen agonist; Estrogen receptors; Human colon cancer cell; P53

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; CYCLIN D1; DIARYLPROPIONITRILE; ESTRADIOL; GELATIN; GELATINASE A; GELATINASE B; PROTEIN P53; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; ESTROGEN RECEPTOR; TP53 PROTEIN, HUMAN;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MTT ASSAY; WESTERN BLOTTING; ZYMOGRAPHY; ADENOCARCINOMA; CELL MOTION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; TUMOR INVASION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84918772015     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16665     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]
2. Razmus I, Jackson J, Wilson D. Hereditary non-polyposis colon cancer: change the name to protect the innocent. Medsurg Nurs 2008; 17: 400-44,410 [PMID: 19248405]
3. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 1998; 82:1197-1207 [PMID: 9506368]
4. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter, case-control study in the United States. Cancer Causes Control 1997; 8:146-158 [PMID: 9134238 DOI: 10.1023/ A:10.1023/ A:1018459911147]
5. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review, J Womens Health Gend Based Med 1999; 8: 1155-1166 [PMID: 10595328 DOI: 10.1089/jwh.l.l999.8.1155]
6. Gustafsson JA. Estrogen receptor beta-a new dimension in estrogen mechanism of action, J Endocrinol 1999; 163: 379-383 [PMID: 10588810 DOI: 10.1677/joe.0.1630379]
7. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 632-640 [PMID: 11212261]
8. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054s-5059s [PMID: 1884381]
9. Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, Kim JY, Lee YC, Kim JM, Park JI, Park HD, No ZS, Lim K, Hwang BD, Kim YS. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res 2004; 10: 4517-4526 [PMID: 15240544 DOI: 10.1158/1078-0432.CCR-04-0084]
10. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392 [PMID: 11923519]
11. Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999; 21: 940-949 [PMID: 10517867]
12. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004; 1705: 69-89 [PMID: 15588763]
13. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26: 767-771 [PMID: 11965442 DOI: 10.1007/ s00268-002-4050-8]
14. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 184-193 [PMID: 12619063 DOI: 10.1002/jso.10210]
15. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046-3050 [PMID: 7708772 DOI: 10.1073/ pnas.92.7.3046]
16. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-3305 [PMID: 9407023 DOI: 10.1101/gad.11.24.3286]
17. Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer 2009; 115: 2063-2070 [PMID: 19298008 DOI: 10.1002/cncr.24254]
18. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sei 2004; 25:177-181 [PMID: 15116721 DOI: 10.1016/j.tips.2004.02.009]
19. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604 [PMID: 12154352 DOI: 10.1038/ nrc864]
20. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T, Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7: 3056-3061 [PMID: 18818522 DOI: 10.4161/cc.7.19.6751]
21. Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC. P53mediated upregulation of DcR1 impairs oxaliplatin/ TRAILinduced synergistic anti-tumour potential in colon cancer cells. Oncogene 2008; 27: 4161-4171 [PMID: 18345033 DOI: 10.1038/ onc.2008.52]
22. Bossi G, Lapi E, S trano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006; 25: 304-309 [PMID: 16170357]
23. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007; 67: 4320-4327 [PMID: 17483345 DOI: 10.1158/0008-5472.CAN-06-2486]
24. Dane K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266 [PMID: 2930999 DOI: 10.1016/S0065-230X(08)60028-7]
25. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573 [PMID: 16405877]
26. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006; 7: 497-508 [PMID: 18369406 DOI: 10.2174/13892020677 9315737]
27. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG. Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression, J Biol Chem 2000; 275: 25322-25329 [PMID: 10840033 DOI: 10.1074/jbc.M002497200]
28. Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang GY. Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem 2006; 289:101-109 [PMID: 16628468 DOI: 10.1007/s11010-006-9153-3]
29. Hsu HH, Cheng SF, Wu CG, Chu CH, Weng YJ, Lin CS, Lee SD, Wu HC, Huang GY, Kuo WW. Apoptotic effects of overexpressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 2006; 49:110-116 [PMID: 16830793]
30. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828 [PMID: 7997877 DOI: 10.1126/sci-ence.7997877]
31. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, Nakata B, Nishiguchi Y, Ikehara T, Okuno M, Sowa M. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 1997; 74: 310-315 [PMID: 9221810]
32. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117 [PMID: 15000152 DOI: 10.1023/A:1025867130437]
33. Murakami A. Modulation of protein quality control systems by food phytochemicals, JClin Biochem Nutr 2013; 52: 215-227 [PMID: 23704811 DOI: 10.3164/jcbn.12-126]